Challenges and Considerations in Sequence Variant Interpretation for Mendelian Disorders

다국어 초록 (Multilingual Abstract)

In 2015, the American College of Medical Genetics and Genomics (ACMG), together with the Association for Molecular Pathology (AMP), published the latest guidelines for the interpretation of sequence variants, which have been widely adopted into clinical practice. Despite these standardized efforts, the degrees of subjectivity and uncertainty allowed by the guidelines can lead to inconsistent variant classification across clinical laboratories, making it difficult to assess the pathogenicity of identified variants. We describe the critical elements of variant interpretation processes and potential pitfalls through practical examples and provide updated information based on a review of recent literature. The variant classification we describe is meant to be applicable to sequence variants for Mendelian disorders, whether identified by single-gene tests, multi-gene panels, exome sequencing, or genome sequencing. Continuing efforts to improve the reproducibility and objectivity of sequence variant interpretation across individuals and laboratories are needed.

참고문헌 (Reference)

1 Li Z, "mirVAFC : A web server for prioritizations of pathogenic sequence variants from exome sequencing data via classifications" 38 : 25-33, 2017

2 Liu X, "dbNSFP : a lightweight database of human nonsynonymous SNPs and their functional predictions" 32 : 894-899, 2011

3 Shearer AE, "Utilizing ethnic-specific differences in minor allele frequency to recategorize reported pathogenic deafness variants" 95 : 445-453, 2014

4 Whiffin N, "Using high-resolution variant frequencies to empower clinical genome interpretation" 19 : 1151-1158, 2017

5 Tang H, "Tools for predicting the functional impact of nonsynonymous genetic variation" 203 : 635-647, 2016

6 "The human genomics variant search engine (VarSome)"

7 Grimm DG, "The evaluation of tools used to predict the impact of missense variants is hindered by two types of circularity" 36 : 513-523, 2015

8 Hoskinson DC, "The current state of clinical interpretation of sequence variants" 42 : 33-39, 2017

9 Pepin MG, "The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories" 18 : 20-24, 2016

10 Muiño E, "Systematic review of cysteine-sparing NOTCH3 missense mutations in patients with clinical suspicion of CADASIL" 18 : E1964-, 2017

11 Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology" 17 : 405-424, 2015

12 Kim YE, "Spectrum of NOTCH3 mutations in Korean patients with clinically suspicious cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy" 35 : 726.e1-726.e6, 2014

13 Nykamp K, "Sherloc : a comprehensive refinement of the ACMG-AMP variant classification criteria" 19 : 1105-1117, 2017

14 Ng PC, "SIFT : Predicting amino acid changes that affect protein function" 31 : 3812-3814, 2003

15 Vears DF, "Reporting practices for variants of uncertain significance from next generation sequencing technologies" 60 : 553-558, 2017

16 Ioannidis NM, "REVEL : an ensemble method for predicting the pathogenicity of rare missense variants" 99 : 877-885, 2016

17 Choi Y, "Predicting the functional effect of amino acid substitutions and indels" 7 : e46688-, 2012

18 Thusberg J, "Performance of mutation pathogenicity prediction methods on missense variants" 32 : 358-368, 2011

19 Amendola LM, "Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium" 98 : 1067-1076, 2016

20 Tabor HK, "Pathogenic variants for Mendelian and complex traits in exomes of 6, 517 European and African Americans : implications for the return of incidental results" 95 : 183-193, 2014

21 Kobayashi Y, "Pathogenic variant burden in the ExAC database : an empirical approach to evaluating population data for clinical variant interpretation" 9 : 13-, 2017

22 Strande NT, "Navigating the nuances of clinical sequence variant interpretation in Mendelian disease" 20 : 918-926, 2018

23 Jagadeesh KA, "M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity" 48 : 1581-1586, 2016

24 Li Q, "InterVar : Clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines" 100 : 267-280, 2017

25 Carter H, "Identifying Mendelian disease genes with the variant effect scoring tool" 14 (14): S3-, 2013

26 박지수, "Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls" 대한암학회 49 (49): 1012-1021, 2017

27 MacArthur DG, "Guidelines for investigating causality of sequence variants in human disease" 508 : 469-476, 2014

28 이재웅, "Genetic Profiles of Korean Patients With Glucose-6-Phosphate Dehydrogenase Deficiency" 대한진단검사의학회 37 (37): 108-116, 2017

29 Jang MA, "Frequency of the moyamoya-related RNF213 p.Arg4810Lys variant in 1,516 Korean individuals" 16 : 109-, 2015

30 Tennessen JA, "Evolution and functional impact of rare coding variation from deep sequencing of human exomes" 337 : 64-69, 2012

31 Ghosh R, "Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines" 18 : 225-, 2017

32 Maxwell KN, "Evaluation of ACMG-guideline-based variant classification of cancer susceptibility and non-cancer-associated genes in families affected by breast cancer" 98 : 801-817, 2016

33 Norton N, "Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era" 5 : 167-174, 2012

34 Sosnay PR, "Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene" 45 : 1160-1167, 2013

35 Jarvik GP, "Consideration of cosegregation in the pathogenicity classification of genomic variants" 98 : 1077-1081, 2016

36 Balmaña J, "Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the Prospective Registry of Multiplex Testing" 34 : 4071-4078, 2016

37 Dong C, "Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies" 24 : 2125-2137, 2015

38 Harrison SM, "Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar" 19 : 1096-1104, 2017

39 Landrum MJ, "ClinVar : public archive of relationships among sequence variation and human phenotype" 42 : D980-D985, 2014

40 Gelb BD, "ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation" 20 : 1334-1345, 2018

41 Rehm HL, "ClinGen–the clinical genome resource" 372 : 2235-2242, 2015

42 최재철, "Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: A Genetic Cause of Cerebral Small Vessel Disease" 대한신경과학회 6 (6): 1-9, 2010

43 Chabriat H, "Cadasil" 8 : 643-653, 2009

44 Lek M, "Analysis of protein-coding genetic variation in 60, 706 humans" 536 : 285-291, 2016

45 Kelly MA, "Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies : recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel" 20 : 351-359, 2018

46 Richards CS, "ACMG recommendations for standards for interpretation and reporting of sequence variations : Revisions 2007" 10 : 294-300, 2008

47 Kazazian HH, "ACMG recommendation for standards for interpretation of sequence variations" 2 : 302-303, 2000

48 Duzkale H, "A systematic approach to assessing the clinical significance of genetic variants" 84 : 453-463, 2013

49 Adzhubei IA, "A method and server for predicting damaging missense mutations" 7 : 248-249, 2010

50 1000 Genomes Project Consortium, "A map of human genome variation from population-scale sequencing" 467 : 1061-1073, 2010

51 1000 Genomes Project Consortium, "A global reference for human genetic variation" 526 : 68-74, 2015

52 Kircher M, "A general framework for estimating the relative pathogenicity of human genetic variants" 46 : 310-315, 2014